APOL1 Nephropathy: From Genetics to Clinical Applications.
Friedman DJ, Pollak MR.
Clin J Am Soc Nephrol. 2021 Feb 8;16(2):294-303. doi: 10.2215/CJN.15161219. Epub 2020 Jul 2.
Abnormal lipoprotein metabolism in diabetic nephropathy.
Hirano T.
Clin Exp Nephrol. 2014 Apr;18(2):206-9. doi: 10.1007/s10157-013-0880-y. Epub 2013 Oct 17.
Lipoprotein abnormalities in diabetic nephropathy.
Hirano T.
Kidney Int Suppl. 1999 Jul;71:S22-4. doi: 10.1046/j.1523-1755.1999.07106.x.
Pathophysiology of Diabetic Dyslipidemia.
Hirano T.
J Atheroscler Thromb. 2018 Sep 1;25(9):771-782. doi: 10.5551/jat.RV17023. Epub 2018 Jul 12.
Normolipidemic lipoprotein glomerulopathy with IgA nephropathy - ApoE Kyoto mutation: a case report.
Yi X, Bai L, Chen K, He Y, Chen J.
Diagn Pathol. 2025 Apr 5;20(1):36. doi: 10.1186/s13000-025-01636-z.
Association of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-to-high-density lipoprotein ratio with diabetic nephropathy.
Sonmezoz GB, Yilmaz M.
Ther Apher Dial. 2025 Jun;29(3):428-436. doi: 10.1111/1744-9987.70008. Epub 2025 Mar 21.
Serum lipoprotein(a) levels and diabetic nephropathy among Japanese patients with type 2 diabetes mellitus.
Senba H, Furukawa S, Sakai T, Niiya T, Miyake T, Yamamoto S, Ueda T, Torisu M, Minami H, Miyaoka H, Onji M, Tanaka K, Matsuura B, Tanigawa T, Hiasa Y, Miyake Y.
J Diabetes Complications. 2016 Jul;30(5):923-7. doi: 10.1016/j.jdiacomp.2016.02.006. Epub 2016 Feb 12.
[Lipoprotein glomerulopathy].
Saito T.
Nihon Jinzo Gakkai Shi. 2007;Suppl 50th Ann:112-6.
Treatment-resistant PLA2R-negative membranous nephropathy responsive to low-density lipoprotein apheresis.
Szymanski JM, Waldman M, Conry-Cantilena C, West KA.
J Clin Apher. 2019 Aug;34(4):495-498. doi: 10.1002/jca.21677. Epub 2018 Dec 10.
Apolipoprotein E-related glomerular disorders.
Saito T, Matsunaga A, Fukunaga M, Nagahama K, Hara S, Muso E.
Kidney Int. 2020 Feb;97(2):279-288. doi: 10.1016/j.kint.2019.10.031. Epub 2019 Nov 22.
